Shenzhen Salubris Pharmaceuticals (Stock Code: 002294), as a leading enterprise of independent innovation in the field of cardiovascular and cerebrovascular disease (Listed China pharmaceutical companies in the top 10), mainly focusing on small molecule drug development and production, and now on Achieving strategic transfer to biopharmaceutical research and development.

Chengdu Genekey Biotech (base in Chengdu) and Salubris Biotherapeutics (base in Maryland), are wholly owned subsidiaries of Salubris Pharmaceuticals. Salubris Biotherapeutics mainly responsible for the early discovery of innovative large molecule drugs And Genekey Biotech has an R & D team with doctoral, master based 156 people. A 6000 square meters of pilot research and development sites with a total value of nearly $100 million of advanced equipment supports our three R & D platform (protein drugs, antibody drugs and gene therapy drugs) for the development of the more than 20 projects. And an up-to-date production base(Genemen bio) of biological drugs in line with the requirements of GMP located in Suzhou.